Free Trial

Commission Signs COVID-19 Drug Contract

EU
European Commission announces has signed a contract with drug firm Gilead
for enough doses of Veklury, the brand name for remdesivir, to treat
30k COVID-19 patients.
  • Full statement:
    https://ec.europa.eu/commission/presscorner/detail/en/ip_20_1416
  • Commission uses the Emergency Support Instrument to make the purchase,
    at the cost of EUR63mn.
  • Remdesivir has been shown to reduce the amount of time a patient shows
    symptoms of COVID-19.
  • Almost all of the world's supply of the drug for the months of June, July,
    and August was purchased by the US in late-June.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.